Abivax (ABVX) Competitors $68.90 -1.11 (-1.59%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. TEVA, SMMT, GMAB, VTRS, ASND, RDY, QGEN, MRNA, BBIO, and VRNAShould you be buying Abivax stock or one of its competitors? The main competitors of Abivax include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Abivax vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories QIAGEN Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Abivax (NASDAQ:ABVX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment. Which has preferable valuation & earnings, ABVX or TEVA? Abivax has higher earnings, but lower revenue than Teva Pharmaceutical Industries. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/ATeva Pharmaceutical Industries$16.63B1.21-$1.64B-$0.16-109.72 Is ABVX or TEVA more profitable? Abivax has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Abivax's return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Teva Pharmaceutical Industries -0.95%46.10%7.18% Which has more volatility & risk, ABVX or TEVA? Abivax has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Do analysts rate ABVX or TEVA? Abivax currently has a consensus target price of $92.33, suggesting a potential upside of 34.01%. Teva Pharmaceutical Industries has a consensus target price of $24.71, suggesting a potential upside of 40.78%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do institutionals & insiders hold more shares of ABVX or TEVA? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ABVX or TEVA? In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than Abivax. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 3 mentions for Abivax. Teva Pharmaceutical Industries' average media sentiment score of 1.56 beat Abivax's score of 0.66 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 14 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryTeva Pharmaceutical Industries beats Abivax on 11 of the 14 factors compared between the two stocks. Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricAbivaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.20B$3.07B$5.76B$9.64BDividend YieldN/A2.22%3.91%4.09%P/E RatioN/A20.4230.8225.11Price / SalesN/A356.30457.82117.10Price / CashN/A41.5625.2228.45Price / Book99.869.569.405.96Net Income-$190.71M-$54.74M$3.26B$265.46M7 Day Performance-4.19%2.68%2.07%1.08%1 Month Performance592.46%4.91%3.92%2.66%1 Year Performance519.60%9.55%29.08%20.32% Abivax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXAbivax3.5268 of 5 stars$68.90-1.6%$92.33+34.0%+545.3%$5.20BN/A0.0061Short Interest ↑TEVATeva Pharmaceutical Industries3.6084 of 5 stars$18.08+1.2%$24.71+36.7%-1.0%$20.48B$16.63B-113.0036,830News CoveragePositive NewsSMMTSummit Therapeutics2.3332 of 5 stars$26.29-1.5%$35.00+33.1%+126.6%$19.83B$700K-26.03110News CoverageAnalyst DowngradeGap DownGMABGenmab A/S3.8673 of 5 stars$23.42+0.5%$37.60+60.5%-13.1%$14.95B$3.12B11.772,682Positive NewsAnalyst RevisionVTRSViatris2.0336 of 5 stars$10.63+0.2%$10.40-2.2%-8.8%$12.37B$14.74B-3.6732,000ASNDAscendis Pharma A/S2.0562 of 5 stars$194.08-2.1%$242.93+25.2%+39.8%$12.13B$490.75M-37.611,017Analyst ForecastRDYDr. Reddy's Laboratories2.8488 of 5 stars$14.26+0.2%$16.95+18.9%-12.8%$11.87B$3.81B21.6027,811News CoverageQGENQIAGEN3.5126 of 5 stars$48.66-1.4%$49.69+2.1%+7.2%$10.97B$1.98B28.755,765News CoverageMRNAModerna4.5429 of 5 stars$28.09+0.2%$43.59+55.2%-67.7%$10.90B$3.24B-3.735,800BBIOBridgeBio Pharma4.692 of 5 stars$49.02-4.5%$61.35+25.2%+100.9%$9.81B$221.90M-11.99400VRNAVerona Pharma PLC American Depositary Share2.3499 of 5 stars$105.79+0.5%$109.00+3.0%+284.8%$8.96B$42.28M-106.8630Short Interest ↓ Related Companies and Tools Related Companies TEVA Competitors SMMT Competitors GMAB Competitors VTRS Competitors ASND Competitors RDY Competitors QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access